Anemia is a common and sometimes debilitating problem among patients with chronic kidney disease (CKD). Anemia can occur when the kidneys become damaged, limiting the production of erythropoietin (EPO ...
Daprodustat had no increased cardiovascular risk, compared with erythropoiesis stimulating agents (ESAs), in treating anemia in patients with chronic kidney disease (CKD) who were on dialysis and not ...
(Reuters) -The U.S. health regulator has declined to approve Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease on safety concerns in non-dialysis patients, the company said on ...
Vadadustat is an investigational drug belonging to a class known as hypoxia-inducible prolyl hydroxylase inhibitors (HIF-PHIs) for the treatment of anemia in chronic kidney disease. John Butler, CEO ...
Could the third time be the charm for an oral HIF-PH inhibitor in the U.S.? GlaxoSmithKline certainly hopes so, with its potential first-in-class medicine now officially up for a decision at the FDA ...
Anemia is a common and sometimes debilitating problem among patients with chronic kidney disease (CKD). Anemia can occur when the kidneys become damaged, limiting the production of erythropoietin (EPO ...
Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) -The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic ...
Less than two weeks after Fibrogen Inc. received an FDA complete response letter for its hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, Evrenzo (roxadustat), Astellas Pharma Inc. and ...
Less than two weeks after Fibrogen Inc. received an FDA complete response letter for its hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, Evrenzo (roxadustat), Astellas Pharma Inc. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback